In Co-Authored Study, Pion and Genentech Demonstrate Effective in vitro Prediction of Drug-Drug Interactions with Acid-Reducing Agents
September 25, 2018
Pion and Genentech (San Francisco) announce publication of an important collaborative research paper, “Using pH Gradient Dissolution with In-Situ Flux Measurement to Evaluate Bioavailability and DDI for Formulated Poorly Soluble Drug Products,” in the Sept. 12 online issue of AAPS PharmSciTech. The paper describes a joint effort by Genentech and Pion to evaluate the suitability of using the MacroFlux™ dissolution-permeation device developed by Pion as an in vitro predictive tool for evaluating the drug-drug interaction (DDI) risks of acid-reducing agents (ARAs) for BCS Class IIb compounds developed by Genentech. Results demonstrated that the apparatus was well suited to the task.
May 25, 2017
Pion Inc. announced today the acquisition of Sirius Analytical Instruments Ltd., headquartered in East Sussex, United Kingdom. Building off the 2016 acquisition of Vortex’s laboratory equipment services division, acquiring Sirius continues Pion’s initiative to grow their global footprint in instrumentation and services. Now with key facilities in both North America and Europe, Pion can provide faster and more efficient support to all customers and distributors.
December 12, 2016
Participants at AAPS were able to see the newest addition to the FLUX family of products. Building on the success and effectiveness of Pion’s PAMPA and µFLUX, Pion continues to invest in and develop solutions for biorelevent data.
October 18, 2016
Pharmaceutical scientists have long sought a reliable method for predicting the absorption potential of finished dosage products prior to clinical trials, but have been frustrated by the limitations of standard dissolution testing, which cannot predict the in vivo response to drug products due to the complex interplay of solubility and permeability in the human body. Now, for the first time, new FLUX testing technology from Pion combines traditional dissolution testing with a repeatable method for assessing the absorption potential of APIs, API/ingredient combinations, or finished dosage products. The result is a single combined test that makes more reliable and realistic IVIVC (in vitro-in vivo correlation) testing and modeling possible.
April 15, 2016
Pion strengthens its presence in the pharmaceutical industry by increasing headcount to cover growing needs in U.S. and EMEIA
April 6, 2016
Pion strengthens its brand in the pharmaceutical industry by increasing its range of service offerings and support personnel across the USA
March 2, 2016
Pion Inc. continues to strengthen position in pharmaceutical R&D with the on-going professional advancement of this leader in the global drug-development industry
October 8, 2015
Pion collaborated with top researchers from Novartis, Nanocopoeia and Leading Universities on Posters for 2015 AAPS.
January 15, 2015
Pion Inc. has joined forces with Dr. Shaukat Ali from BASF to develop a new protocol for testing drug supersaturation.
June 12, 2014
Pion launches the latest and revoulutionary in situ concentration monitoring software the Au PRO
February 25, 2014
January 14, 2014
March 13, 2013
Considerable improvements were made to the MiniBath module of the µDISS ProfilerPLUS™ including *8* individual sample stations and computer controlled stirring.
March 13, 2013
March 13, 2013
March 8, 2013